Significance: Cell senescence is implicated in many age-related diseases. Drugs which
postpone or reverse cellular senescence (SENO drugs) have been developed and three of these
drugs are in human clinical trials. The availability of an inexpensive, whole-animal model of SENO
drug action will accelerate development of new treatments of Alzheimer’s Disease.
Background: SENO drugs ameliorate numerous age-related pathologies through a common
pharmacological action: the selective killing or alteration of senescent cells. SENO drugs are
expected to postpone diverse causes of human mortality including Parkinson’s Disease,
Alzheimer’s Disease, and atherosclerosis, as well as cancer metastasis and recurrence. We
propose to study SENO drugs, targeting three distinct pathways. These pathways lead to
alternative responses characterized by distinct levels of AMP Kinase and P53.
C. elegans transgenic strains have been engineered to express the amyloidogenic human
proteins amyloid-beta (Aß) and tau. We found that treatment with a SENO drug (piperlongumine)
resulted in longer life in the wild-type and postponed paralysis in Aß-expressing transgenic worm
strains, and have since found a similar effect with a second SENO drug (KU60019). We propose
to extend these studies by applying a representative set of five SENO drugs to wild-type
nematodes and then apply single-cell RNA-Seq, to search for common seno-drug-driven
transcriptional changes within and between specific cell types.